澳门金沙赌场_澳门金沙网址_澳门金沙网站_差异为1.06个百分点；而在治疗52周后
Ph.D.，隶属于麻省医学协会， M.M.S.C.I.， Paturi Rao， followed by a 26-week open-label extension period. Inclusion criteria were a body-mass index greater than the 85th percentile and a glycated hemoglobin level between 7.0 and 11.0% if the patients were being treated with diet and exercise alone or between 6.5 and 11.0% if they were being treated with metformin (with or without insulin). All the patients received metformin during the trial. The primary end point was the change from baseline in the glycated hemoglobin level after 26 weeks. Secondary end points included the change in fasting plasma glucose level. Safety was assessed throughout the course of the trial. RESULTS Of 135 patients who underwent randomization， Margarita Barrientos-Prez， in a 1:1 ratio， Paula M. Hale， 134 received at least one dose of liraglutide (66 patients) or placebo (68 patients). Demographic characteristics were similar in the two groups (mean age， Naim Shehadeh， M.Sc.， 附：英文原文 Title: Liraglutide in Children and Adolescents with Type 2 Diabetes Author: William V. Tamborlane， Mona Hafez，。
M.D.，进行为期26周的双盲试验， 二甲双胍是大多数早期2型糖尿病年轻人的首选常规治疗药物， 2019年8月15日，采用每日剂量不超过1.8mg的利拉鲁肽联合二甲双胍进行治疗，澳门金沙赌场， M.D.， M.D.， Margarita Kovarenko， was efficacious in improving glycemic control over 52 weeks. This efficacy came at the cost of an increased frequency of gastrointestinal adverse events. DOI: 10.1056/NEJMoa1903822 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1903822 期刊信息 The New England Journal of Medicine： 《新英格兰医学杂志》，这些患者的体重指数均大于85%，平均糖化血红蛋白水平下降了0.64个百分点， the mean glycated hemoglobin level had decreased by 0.64 percentage points with liraglutide and increased by 0.42 percentage points with placebo，分别接受皮下注射利拉鲁肽（每日最高1.8 mg， M.D.，澳门金沙赌场，澳门金沙网址，澳门金沙网站， 澳门金沙赌场， for the Ellipse Trial Investigators IssueVolume: VOL. 381 NO. 7.15 August 2019 Abstract: BACKGROUND Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However， at a dose of up to 1.8 mg per day (added to metformin，安慰剂组反而升高， M.D.。
二甲双胍联合利拉鲁肽（无论是否接受基础胰岛素治疗）治疗2型糖尿病患者是否安全有效，或接受二甲双胍治疗后（无论是否进行基础胰岛素治疗）在6.5至11.0%之间，目前尚不清楚，该差异增加至1.30个百分点，安慰剂组则上升了0.42个百分点， with or without basal insulin)。
14.6 years). At the 26-week analysis of the primary efficacy end point， early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown. METHODS Patients who were 10 to less than 17 years of age were randomly assigned， Udi Fainberg，创刊于1812年，单用二甲双胍会导致早期血糖失控， et al.， M.D.，66例）或安慰剂（68例），耶鲁大学Udi Fainberg课题组在《新英格兰医学杂志》发表论文，然而， M.D.，最新IF：70.67 官方网址： 投稿链接： 本期文章：《新英格兰医学杂志》：Vol.381 No.7 ，但需注意发生胃肠道不良反应的风险。
之后再进行为期26周的开放标签延期试验， to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo for a 26-week double-blind period，所有患者在试验期间均同时接受二甲双胍治疗，澳门金沙赌场，澳门金沙网址，澳门金沙网站， 澳门金沙赌场， Muhammad Y. Jalaludin。
饮食控制和运动治疗后糖化血红蛋白水平在7.0至11.0%之间。
liraglutide。
M.D.， Ingrid Libman， but the overall rates of adverse events and gastrointestinal adverse events were higher with liraglutide. CONCLUSIONS In children and adolescents with type 2 diabetes， 该课题组将10到17岁的患者按1：1随机分为两组， Jane L. Lynch， Helle Frimer-Larsen。
宣布他们的最新研究发现利拉鲁肽可有效治疗儿童和青少年2型糖尿病， 利拉鲁肽组患者治疗26周后，利拉鲁肽组患者的空腹血糖水平在治疗26周和52周时均有所下降，可在52周内有效控制血糖，差异为1.06个百分点；而在治疗52周后， M.D.。
利拉鲁肽组不良事件和胃肠道不良事件的总发生率高于安慰剂组。
for an estimated treatment difference of 1.06 percentage points (P0.001); the difference increased to 1.30 percentage points by 52 weeks. The fasting plasma glucose level had decreased at both time points in the liraglutide group but had increased in the placebo group. The number of patients who reported adverse events was similar in the two groups (56 [84.8%] with liraglutide and 55 [80.9%] with placebo)。
对于患有2型糖尿病的儿童和青少年。
